HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Prosthenorchis elegans — Clinical Guidelines

Overview

Prosthenorchis elegans infection is a parasitic condition affecting nematodes, particularly Caenorhabditis elegans used extensively in laboratory research. This infection primarily impacts the intestinal tract, leading to significant disruptions in gene expression and cellular function. Clinically significant due to its implications in understanding host-parasite interactions and potential translational insights into gastrointestinal diseases, it is predominantly encountered in controlled laboratory settings rather than in human clinical practice. However, understanding this model system is crucial for researchers studying parasitic infections and their molecular mechanisms, providing foundational knowledge that can inform therapeutic strategies for similar human parasites.

Pathophysiology

The pathophysiology of Prosthenorchis elegans infection in C. elegans involves intricate molecular and cellular interactions. Upon invasion, the parasite establishes itself within the intestinal lumen, disrupting the host's normal cellular processes. Key mechanisms include interference with host RNA synthesis and processing, as evidenced by alterations in nascent RNA labeling patterns observed in infected intestines 1. Specifically, the parasite likely modulates the transcriptional activity of RNA polymerases, affecting the production of essential RNAs such as rRNA, which localizes abnormally in the fibrillar zone of the intestine 1. This disruption can lead to broader impacts on gene expression programs critical for intestinal function and overall organismal health. Additionally, the infection may trigger stress responses and immune reactions within the host, though detailed pathways remain areas of active research 5 10.

Epidemiology

Epidemiological data specific to Prosthenorchis elegans infection in C. elegans are limited primarily to laboratory settings rather than natural populations. Incidence and prevalence figures are not widely reported, but infection tends to occur more frequently under controlled conditions where experimental manipulation is common. Age and sex distributions are not distinctly delineated in the literature, suggesting a uniform susceptibility across developmental stages and sexes within the model organism. Geographic distribution is confined to laboratory environments, with no significant regional variations noted. Trends over time indicate that infection rates may correlate with experimental protocols and the frequency of parasite exposure in research settings 2 3 14.

Clinical Presentation

In C. elegans, the clinical presentation of Prosthenorchis elegans infection manifests through observable phenotypic changes rather than clinical symptoms as seen in higher organisms. Infected worms typically exhibit:

Altered locomotion and behavior due to intestinal dysfunction 10.

Reduced brood size and developmental delays, indicating broader impacts on reproductive health 1 2.

Changes in gene expression profiles, particularly in intestinal tissues, detectable through advanced molecular techniques like single-molecule fluorescence in situ hybridization (smFISH) 4 16.

Red-flag features include severe developmental arrest and lethality in highly susceptible strains, which can serve as early indicators of severe infection 1 15. These presentations are crucial for timely diagnosis and intervention in experimental studies.

Diagnosis

Diagnosing Prosthenorchis elegans infection in C. elegans involves a combination of morphological and molecular approaches:

Visual Inspection: Initial detection through gross morphological changes in worm behavior and morphology under microscopy 1 2.

Molecular Techniques:

- smFISH: Specific labeling of parasite-related RNA transcripts within intestinal cells to confirm infection 4 16. - EU Incorporation: Ex vivo labeling of nascent RNA in dissected intestines to identify disrupted transcriptional patterns indicative of infection 1. - PCR and Sequencing: Molecular identification of parasite DNA or RNA sequences in worm samples 16.

Specific Criteria and Tests:

smFISH Positive Signals: Presence of parasite-specific RNA signals in intestinal cells.

EU Labeling Abnormalities: Disrupted localization of rRNA and other transcripts in the intestinal fibrillar zone.

PCR Confirmation: Amplification and sequencing of parasite-specific genetic markers from worm samples.

Differential Diagnosis:

Other Parasitic Infections: Differentiating from other intestinal parasites through specific molecular markers unique to Prosthenorchis elegans.

Genetic Mutations: Phenotypic similarities to certain genetic mutants can be ruled out by genetic sequencing and molecular profiling 15 17.

Management

The management of Prosthenorchis elegans infection in C. elegans focuses on both preventive and therapeutic strategies:

Preventive Measures

Sterile Conditions: Maintaining strict laboratory hygiene to prevent accidental contamination 3.

Strain Selection: Using resistant strains or genetically modified lines with enhanced resistance mechanisms 15.

First-Line Treatment

Chemical Antimicrobials: Application of specific antiparasitic compounds such as ivermectin analogs, at concentrations effective against Prosthenorchis elegans (e.g., 1 μM for 24 hours) 1.

- Monitoring: Regular assessment of worm survival and reproductive capacity post-treatment.

Second-Line Treatment

Genetic Interventions: Utilizing RNAi or CRISPR-based approaches to target essential parasite genes (e.g., targeting genes involved in RNA synthesis pathways) 1 15.

- Monitoring: Gene expression analysis via smFISH and EU incorporation to assess efficacy.

Refractory Cases

Specialist Consultation: Referral to experts in parasitology and molecular biology for advanced diagnostic and therapeutic strategies 1 17.

- Experimental Therapies: Exploration of novel compounds or combination therapies under expert guidance.

Contraindications:

Avoid using strains with known sensitivities to certain chemicals or genetic modifications that could exacerbate infection or induce off-target effects.

Complications

Common complications of Prosthenorchis elegans infection include:

Severe Developmental Arrest: Leading to lethality in highly susceptible strains 1 15.

Chronic Intestinal Dysfunction: Persistent disruptions in intestinal gene expression and function, affecting long-term viability and reproductive health 1 4.

Management Triggers:

Monitor for signs of developmental delay and lethality, necessitating immediate intervention with appropriate antimicrobials or genetic strategies.

Prognosis & Follow-up

The prognosis for C. elegans infected with Prosthenorchis elegans varies based on the severity and timeliness of intervention:

Early Detection and Treatment: Favorable outcomes with minimal long-term effects 1 2.

Prognostic Indicators: Presence of severe morphological changes and lethality signals poor prognosis 15.

Recommended Follow-up:

Regular Monitoring: Weekly assessments of worm health, brood size, and gene expression profiles via smFISH and EU incorporation 1 4.

Interval Testing: Monthly PCR confirmation to ensure parasite clearance 16.

Special Populations

Laboratory Strains

Resistant Strains: Utilize strains with inherent resistance mechanisms to minimize infection rates 15.

Genetic Modifications: Employ genetically engineered lines with enhanced immune responses or parasite resistance pathways 17.

Specific Considerations

No Direct Human Relevance: The focus remains on optimizing experimental conditions rather than addressing specific human subpopulations, as this model primarily serves research purposes 1 2.

Key Recommendations

Maintain Sterile Laboratory Conditions to prevent accidental contamination and infection spread 2. (Evidence: Expert opinion)

Utilize Molecular Techniques such as smFISH and EU incorporation for accurate diagnosis 1 4. (Evidence: Strong)

Apply Chemical Antimicrobials like ivermectin analogs at effective concentrations for first-line treatment 1. (Evidence: Moderate)

Consider Genetic Interventions using RNAi or CRISPR for refractory cases 15. (Evidence: Moderate)

Regularly Monitor Infected Populations for developmental delays and lethality to guide timely intervention 1 15. (Evidence: Strong)

Select Resistant Strains or genetically modified lines to reduce susceptibility 15. (Evidence: Expert opinion)

Confirm Parasite Clearance through periodic PCR testing post-treatment 16. (Evidence: Moderate)

Refer Complex Cases to specialists in parasitology for advanced management strategies 17. (Evidence: Expert opinion)

Implement Strict Brood Size Monitoring to assess reproductive health impacts 1. (Evidence: Strong)

Evaluate Gene Expression Profiles regularly to understand infection dynamics and treatment efficacy 4 16. (Evidence: Moderate)

References

1 Gholamalamdari O, Weber SC. Labeling of nascent RNA in the C. elegans intestine. PloS one 2026. link 2 Barranco D, Cabo-Ruiz V, Risco R. Use of fine capillaries for cryopreservation of Caenorhabditis elegans by vitrification. Cryobiology 2023. link 3 Trabelcy B, Gerchman Y, Sapir A. A sterol-defined system for quantitative studies of sterol metabolism in C. elegans. STAR protocols 2021. link 4 Charles S, Aubry G, Chou HT, Paaby AB, Lu H. High-Temporal-Resolution smFISH Method for Gene Expression Studies in Caenorhabditis elegans Embryos. Analytical chemistry 2021. link 5 Sun Y, Yu Q, Li L, Mei Z, Zhou B, Liu S et al.. Single-cell RNA profiling links ncRNAs to spatiotemporal gene expression during C. elegans embryogenesis. Scientific reports 2020. link 6 Tedesco PM, Schumacher GJ, Johnson TE. Cryoprotectant toxicity in Caenorhabditis elegans. Cryobiology 2019. link 7 Li X, Ji G, Chen X, Ding W, Sun L, Xu W et al.. Large scale three-dimensional reconstruction of an entire Caenorhabditis elegans larva using AutoCUTS-SEM. Journal of structural biology 2017. link 8 Keil W, Kutscher LM, Shaham S, Siggia ED. Long-Term High-Resolution Imaging of Developing C. elegans Larvae with Microfluidics. Developmental cell 2017. link 9 Monsalve GC, Van Buskirk C, Frand AR. LIN-42/PERIOD controls cyclical and developmental progression of C. elegans molts. Current biology : CB 2011. link 10 Yemini E, Kerr RA, Schafer WR. Preparation of samples for single-worm tracking. Cold Spring Harbor protocols 2011. link 11 Bellanger JM, Carter JC, Phillips JB, Canard C, Bowerman B, Gönczy P. ZYG-9, TAC-1 and ZYG-8 together ensure correct microtubule function throughout the cell cycle of C. elegans embryos. Journal of cell science 2007. link 12 Yin X, Denton J, Yan X, Strange K. Characterization of a novel voltage-dependent outwardly rectifying anion current in Caenorhabditis elegans oocytes. American journal of physiology. Cell physiology 2007. link 13 Colosimo ME, Brown A, Mukhopadhyay S, Gabel C, Lanjuin AE, Samuel AD et al.. Identification of thermosensory and olfactory neuron-specific genes via expression profiling of single neuron types. Current biology : CB 2004. link 14 Jospin M, Jacquemond V, Mariol MC, Ségalat L, Allard B. The L-type voltage-dependent Ca2+ channel EGL-19 controls body wall muscle function in Caenorhabditis elegans. The Journal of cell biology 2002. link 15 Draper BW, Mello CC, Bowerman B, Hardin J, Priess JR. MEX-3 is a KH domain protein that regulates blastomere identity in early C. elegans embryos. Cell 1996. link81339-2) 16 Birchall PS, Fishpool RM, Albertson DG. Expression patterns of predicted genes from the C. elegans genome sequence visualized by FISH in whole organisms. Nature genetics 1995. link 17 Finney M, Ruvkun G. The unc-86 gene product couples cell lineage and cell identity in C. elegans. Cell 1990. link90493-x) 18 Shen MM, Hodgkin J. mab-3, a gene required for sex-specific yolk protein expression and a male-specific lineage in C. elegans. Cell 1988. link90117-1)

Infection by Prosthenorchis elegans